stockrow
Friday 6 November 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
35.01
2.48
+7.62%
Follow PHVS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 36 | 36 | 215 | +145.2% | |
| Gross margin, % | — | — | — | 0.00 | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (5) | (9) | (30) | (50) | (80) | (108) | (143) | (197) | (197) | +68.5% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (5) | (9) | (30) | (50) | (80) | (108) | (143) | (197) | (193) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (1.05) | (1.85) | (6.12) | (1.66) | (2.39) | (2.84) | (2.68) | (3.36) | (3.05) | +18.1% | ||||||
| Cash flow | — | — | (0.95) | (1.54) | (5.06) | (1.73) | (2.11) | (2.62) | (2.41) | (2.62) | (2.62) | +15.5% | ||||||
| Capex | — | — | 0.00 | 0.00 | (0.01) | (0.01) | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.95) | (1.54) | (5.07) | (1.74) | (2.11) | (2.63) | (2.42) | (2.62) | (2.62) | +15.6% | ||||||
| Book value | — | — | 1.17 | 4.32 | 22.56 | 7.97 | 4.68 | 10.83 | 5.36 | 5.19 | 5.14 | +23.7% | ||||||
| Shares, m | — | — | 5 | 5 | 5 | 30 | 34 | 38 | 54 | 59 | 64 | +42.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (5) | (7) | (25) | (53) | (71) | (101) | (130) | (155) | (178) | +65.2% | |||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | +52.0% | ||||||
| Free cash flow | — | — | (5) | (7) | (25) | (53) | (71) | (101) | (131) | (155) | (178) | +65.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 6 | 21 | 109 | 242 | 157 | 415 | 288 | 305 | 348 | +76.7% | |||||
| Net debt | — | — | (6) | (23) | (113) | (248) | (170) | (423) | (303) | (329) | (370) | +76.6% | ||||||
| Shareholders’ equity | — | — | 6 | 21 | 109 | 242 | 157 | 416 | 290 | 307 | 350 | +76.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (163.85) | (61.26) | (42.83) | (27.59) | (37.61) | (35.90) | (38.90) | (60.57) | (64.43) | +103.3 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | (38.45) | (67.88) | (45.57) | (28.73) | (40.24) | (38.11) | (41.18) | (66.63) | (71.50) | (28.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 14 | 34 | 65 | 82 | 108 | 129 | — | +55.9% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Pharvaris N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics Inc | $3.0B | 16.7× | 14.0× | +5.12% (above 0%: growing) | +46.67% (above 0%: growing) | +1,709.49% (above 0%: growing) | 70.81% | 48.02% | Compare |
| VCEL Vericel Corporation | $2.7B | 77.8× | 72.9× | +26.47% (above 0%: growing) | +180.00% (above 0%: growing) | −19.39% (below 0%: shrinking) | 73.34% | 14.27% | Compare |
| PHVS Pharvaris N.V. | $2.3B | — (loss-making) | — | — | n/m | −17.31% (below 0%: shrinking) | 0.00% | 0.00% | |
| PVLA Palvella Therapeutics, Inc. | $2.3B | — (loss-making) | — (loss-making) | −99.09% (below 0%: shrinking) | n/m | −136.38% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | — (loss-making) | — (loss-making) | +5,406.90% (above 0%: growing) | n/m | −21.76% (below 0%: shrinking) | 100.00% | (230.58%) | Compare |
| CLDX Celldex Therapeutics, Inc. | $2.2B | — (loss-making) | — (loss-making) | −96.83% (below 0%: shrinking) | n/m | −35.45% (below 0%: shrinking) | 100.00% | (366,468.18%) | Compare |
| RXRX Recursion Pharmaceuticals, Inc. | $2.2B | — (loss-making) | — (loss-making) | +258.49% (above 0%: growing) | n/m | +33.83% (above 0%: growing) | 45.85% | (663.95%) | Compare |
| IMNM Immunome, Inc. | $2.1B | — (loss-making) | — (loss-making) | +69.84% (above 0%: growing) | n/m | −26.96% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| BHVN Biohaven Ltd. | $2.1B | — (loss-making) | — (loss-making) | +131.43% (above 0%: growing) | n/m | +26.55% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $2.2B | — | — | +48.16% | — | −20.57% | 86.67% | 0.00% |